Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. Molecular Analysis for Precision Oncology Congress 2023

What are the current roadblocks to histology agnostic biomarker driven approvals?

The regulator perspective on pan-cancer drug development (FDA)

Date

06 Oct 2023

Session

What are the current roadblocks to histology agnostic biomarker driven approvals?

Topics

Clinical Research;  Rare Cancers;  Cancer Diagnostics;  Therapy

Tumour Site

Presenters

Steven Lemery

Authors

S. Lemery

Author affiliations

  • Center For Drug Evaluation And Research, US FDA - Federal Drug Administration, 20993 - Silver Spring/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A

Presenter: Francesco Pignatti

Session: What are the current roadblocks to histology agnostic biomarker driven approvals?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.